Why
Liposomal
Amphotericin
B
Liposomal
Amphotericin
B
Why Liposomal Amphotericin B
I Am… Liposomal Amphotericin B: Ready to take
on Hamza's Aspergillus infection7,8
on Hamza's Aspergillus infection7,8
Liposomal Amphotericin B was selected to treat
Hamza's Aspergillus infection based on:
Hamza's Aspergillus infection based on:
Fungicidal (rather than fungistatic) activity
in vitro against Aspergillus8–10
in vitro against Aspergillus8–10
Liposomal Amphotericin B has improved fungicidal
activity vs. echinocandins and azoles, against
the most clinically important yeast and moulds8,10
activity vs. echinocandins and azoles, against
the most clinically important yeast and moulds8,10
Timelines for treatment initiation11,12
In a high-risk setting, prompt treatment with
Liposomal Amphotericin B can lead to improved
clinical outcomes vs. delaying treatment11,12
Liposomal Amphotericin B can lead to improved
clinical outcomes vs. delaying treatment11,12
A well-established tolerability and
safety profile*
safety profile*
Very common adverse events associated with
Liposomal Amphotericin B treatment include rigors,
pyrexia, hypokalaemia, nausea and vomiting7
Liposomal Amphotericin B treatment include rigors,
pyrexia, hypokalaemia, nausea and vomiting7
*Please refer to the Liposomal Amphotericin B Summary of Product Characteristics for detailed information on safety profile.
DAY 6-8
Liposomal Amphotericin B initiated
DAY 13
No improvement
